Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen W Gutkin

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Medical Research and Opinion|July 19, 2006
Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) studyTerry A Jacobson, Stephen W Gutkin, Charles R Harper
European Journal of Endocrinology|March 7, 2008
Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?Luc F Van Gaal, Stephen W Gutkin, Michael A Nauck
Journal of Cardiovascular Pharmacology|April 23, 2008
Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomesMadiha Abdel-Maksoud, Vasilisa Sazonov, Stephen W Gutkin, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 21, 2018
A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United StatesWenjie Zhang, Tony B Amos, Stephen W Gutkin, et al.
Child and Adolescent Psychiatry and Mental Health|May 17, 2011
Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studiesRuth A Dickson, Ellen Maki, Christopher Gibbins, et al.
Journal of the American Academy of Nurse Practitioners|June 9, 2011
Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall healthRichard Sadovsky, Gerald B Brock, Mikel Gray, et al.
Current Medical Research and Opinion|December 7, 2007
Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemiaGerd Assmann, Frank Kannenberg, Dena R Ramey, et al.
Cancer Diagnosis & Prognosis|March 4, 2026
<i>BCR::ABL1</i> Mutational Profiling in US Patients With Chronic-phase Chronic Myeloid Leukemia on Tyrosine Kinase InhibitorsFadi G Haddad, Elias J Jabbour, Stephen W Gutkin, et al.
Current Medical Research and Opinion|February 6, 2014
Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a primary-care databaseKevin Jameson, Qiaoyi Zhang, Changgeng Zhao, et al.
The Journal of Sexual Medicine|October 23, 2009
Sexual satisfaction in men with erectile dysfunction: correlates and potential predictorsStanley E Althof, Jacques Buvat, Stephen W Gutkin, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Medical Research and Opinion|July 19, 2006
Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) studyTerry A Jacobson, Stephen W Gutkin, Charles R Harper
European Journal of Endocrinology|March 7, 2008
Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?Luc F Van Gaal, Stephen W Gutkin, Michael A Nauck
Journal of Cardiovascular Pharmacology|April 23, 2008
Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomesMadiha Abdel-Maksoud, Vasilisa Sazonov, Stephen W Gutkin, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 21, 2018
A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United StatesWenjie Zhang, Tony B Amos, Stephen W Gutkin, et al.
Child and Adolescent Psychiatry and Mental Health|May 17, 2011
Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studiesRuth A Dickson, Ellen Maki, Christopher Gibbins, et al.
Journal of the American Academy of Nurse Practitioners|June 9, 2011
Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall healthRichard Sadovsky, Gerald B Brock, Mikel Gray, et al.
Current Medical Research and Opinion|December 7, 2007
Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemiaGerd Assmann, Frank Kannenberg, Dena R Ramey, et al.
Cancer Diagnosis & Prognosis|March 4, 2026
<i>BCR::ABL1</i> Mutational Profiling in US Patients With Chronic-phase Chronic Myeloid Leukemia on Tyrosine Kinase InhibitorsFadi G Haddad, Elias J Jabbour, Stephen W Gutkin, et al.
Current Medical Research and Opinion|February 6, 2014
Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a primary-care databaseKevin Jameson, Qiaoyi Zhang, Changgeng Zhao, et al.
The Journal of Sexual Medicine|October 23, 2009
Sexual satisfaction in men with erectile dysfunction: correlates and potential predictorsStanley E Althof, Jacques Buvat, Stephen W Gutkin, et al.
Pageof 2